Table II.
Demographics and clinical characteristics of enrolled patients.
| T790M detected by ACB-ARMS PCR | ||||
|---|---|---|---|---|
| Characteristic | Total, n (%) | Positive, n (%) | Negative, n (%) | P-value |
| Age, years | 0.363 | |||
| ≤60 | 17 (63.0) | 5 (18.5) | 12 (44.4) | |
| >60 | 10 (37.0) | 1 (3.7) | 9 (33.3) | |
| Gender | 1.000 | |||
| Female | 15 (55.6) | 3 (11.1) | 12 (44.4) | |
| Male | 12 (44.4) | 3 (11.1) | 9 (33.3) | |
| Smoking status | 0.290 | |||
| Never-smoker | 20 (74.1) | 3 (11.1) | 17 (63.0) | |
| Smoker | 7 (25.9) | 3 (11.1) | 4 (14.8) | |
| Pathology | 0.222 | |||
| Squamous | 1 (3.7) | 1 (3.7) | 0 (0.0) | |
| Adenocarcinoma | 26 (96.3) | 5 (18.5) | 21 (77.8) | |
| EGFR activating mutation | 0.648 | |||
| 19 Del | 13 (48.1) | 2 (7.4) | 11 (40.7) | |
| 21 L858R | 14 (51.9) | 4 (14.8) | 10 (37.0) | |
| Stage | 1.000 | |||
| IA-IIIA | 5 (18.5) | 1 (3.7) | 4 (14.8) | |
| IIIB-IV | 22 (81.5) | 5 (18.5) | 17 (63.0) | |
| Line of TKI therapy | 0.628 | |||
| First | 9 (33.3) | 1 (3.7) | 8 (29.6) | |
| Second or multiple | 18 (66.7) | 5 (18.5) | 13 (48.1) | |
ACB-ARMS PCR, allele-specific competitive blocker-amplification refractory mutation system TaqMan quantitative polymerase chain reaction; TKI, tyrosine kinase inhibitor.